Bharat Biotech International (BBIL), a leading manufacturer of vaccines and biotherapeutics, has secured patent rights for its Anti-Staphylococcal Molecule 'Lysostaphin' in US, Europe, China and Australia.

Lysostaphin is a potent anti-Staphylococcal therapeutic with a targeted specificity against Staphylococcus aureus (S.aureus). It is a glycylglycine endopeptidase that rapidly cleaves the peptidoglycan backbone of S.aureus, lysing the cell in all its metabolic states.

S. aureus causes a broad spectrum of diseases, including superficial lesions, such as wound infections; systemic and life-threatening conditions, such as endocarditis, osteomyelitis, pneumonia, brain abscesses, meningitis, and bacteremia; and toxinoses, such as food poisoning, scalded skin syndrome, and toxic shock syndrome.

According to Dr Krishna Ella, chairman and managing director, Bharat Biotech, patent rights for Lysostaphin is a significant milestone in our new therapeutic product development program and paves way to develop products for regulated markets, in addition to India. A pre-IND (Investigational New Drug (IND) Application meeting) of the pre-clinical data has already been held with US FDA.

Lysostaphin being bactericidal in action is indifferent to antibiotic resistance and could be drug of choice for treating life threatening S.aureus bacteremia caused drug resistant S.aureus.

Bharat Biotech specializes in product-oriented research, development and manufacturing of vaccines and biotherapeutics and it has been in the forefront of developing and manufacturing world class vaccines and it is currently developing swine flu vaccine.

The company has 13 Patents filed in India, 12 Patents filed Internationally. And it has been granted 8 patents in India and 5 patents abroad.